JUN 12, 2017 1:33 PM PDT

Nanoparticle "Immunoswitch" Reduces Cancer Growth

WRITTEN BY: Kara Marker

Johns Hopkins scientists have a new tool against cancer, and it’s a thousand times smaller than a human hair: a nanoparticle immunoswitch. New studies with this new approach have shown in mouse models to drastically slow - sometimes completing stopping - the growth of melanoma and colon cancer, and usage against other types of cancer are on the horizon.

These are T cells (red) and tumor cells (green) incubated with control particles (left) or immunoswitch particles (right). Credit: Alyssa Kosmides

The best defense is a good offense 

The new approach improves upon the limitations of current immunotherapy techniques, specifically checkpoint inhibitor-based treatments. These drugs only work for some cancer patients and only against certain cancer types. For example, studies have shown that checkpoint inhibitors are about 30 percent effective against melanoma, bladder cancer, Hodgkin’s lymphoma, and non-small cell lung cancer. While giving a patient more of a drug might be more effective, concentrations of these drugs at a certain level can cause extremely undesirable side effects.

"The improvement here was to make, for the first time, a nanoparticle that can interact simultaneously with multiple types of cells in the complex tumor microenvironment, dramatically increasing its effectiveness,” explained Jonathan P. Schneck, MD, PhD from Johns Hopkins.

Schneck conducted his study with the nanoparticle immunoswitch using two different immunotherapy strategies, with two different types of antibodies bound to separate nanoparticles: programmed death ligand 1 (PD-L1) inhibitor and a T cell stimulator. Both nanoparticles were injected into a mouse model of melanoma, and Schneck soon observed the significant halt done to tumor progression. These mice lived much longer than their companions who received no treatment. Later, Schneck saw even more dramatic results in mouse models of colon cancer.

"The double-duty immunoswitch particles were clearly more effective than a mixture of nanoparticles that each targeted just one protein and acted in a synergistic fashion, but we don't yet know why," Schneck said. "It may be that the immunoswitch particles' success comes from bringing T cells and their targeted tumor cells into close proximity."

The particles owe their success, in part, to their “enhanced permeability and retention effect,” meaning they are more easily absorbed by tumor cells than by healthy cells, keeping the healthy cells safe. Plus, each individual nanoparticle could hold multiple antibodies at one time, allowing for a multifaceted attack on tumors and less of a chance of side effects.

In the future, Schneck and his team plan on improving the nanoparticle immunoswitch by looking for even more effective antibody combinations. And with the possibility of tailoring different therapies for specific types of cancer, this new technology could be a great tool.

The present study was published in the journal ACS Nano.

 

Source: Johns Hopkins Medicine

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 02, 2021
Immunology
Pumping the Brakes on Stomach Cancer Progression
FEB 02, 2021
Pumping the Brakes on Stomach Cancer Progression
By the time stomach cancer is diagnosed, it’s often bad news for patients. The disease often presents with relativ ...
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
APR 06, 2021
Immunology
Lymphoma Patient Cured by "Reeducating" their Immune System
APR 06, 2021
Lymphoma Patient Cured by "Reeducating" their Immune System
Australian researchers have used a breakthrough therapy to cure a patient diagnosed with a rare brain lymphoma, a form o ...
MAY 10, 2021
Coronavirus
Researchers Create a Vaccine For Multiple SARS Viruses, Including COVID-19 & Variants
MAY 10, 2021
Researchers Create a Vaccine For Multiple SARS Viruses, Including COVID-19 & Variants
The pandemic virus SARS-CoV-2 has changed the world in devastating ways, taking hundreds of thousands of lives & new var ...
JUN 01, 2021
Immunology
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
JUN 01, 2021
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
Seasonal flu vaccines only work around 40 to 60 percent of the time, says the U.S. Centers for Disease Control and Preve ...
JUN 11, 2021
Cell & Molecular Biology
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
JUN 11, 2021
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
The immune system can detect and destroy pathogenic and cancerous cells, but sometimes those dangerous cells can evade t ...
Loading Comments...